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Specific saturable receptors for epidermal growth factor (EGF) of high affinity (& 1.7 x lo9 M-l) have 
been demonstrated on porcine thyroid membranes. Optimal conditions for EGF binding have been 
determined. TSH and other peptide hormones do not inhibit the binding of “‘1-EGF and EGF does not 
inhibit “‘1-TSH binding to thyroid membranes. The results suggest hat EGF may be involved in the 
regulation of thyroid follicular cell growth and function. 
Thyroid Epidermal growth factor Receptor Thyrotrophin 
1. INTRODUCTION 
Epidermal growth factor (EGF) is a polypeptide 
molecule that has potent mitogenic effects on cells 
of various origins [1,2], and the presence of 
specific, high affinity, saturable receptors has been 
demonstrated in many cell types [3]. 
Previous reports on the effect of EGF on thyroid 
cells have been conflicting. Some groups have 
reported an effect of EGF on thyroid cell prolifera- 
tion in culture [4-61, others have reported no such 
effect [7-91. Most relevant to the clarification of 
this issue is the demonstration of EGF receptors on 
thyroid cell membranes. A previous study has fail- 
ed to detect EGF receptors on bovine thyroid 
membranes [lo]. 
Here, we demonstrate the presence of specific, 
high affinity, saturable EGF receptors on porcine 
thyroid cell membranes. 
2. MATERIALS AND METHODS 
2.1. Iodination of EGF 
EGF (Bethesda Res. Labs., Cambridge) ex- 
tracted from male mouse submaxillary glands, was 
iodinated using Na”‘I carrier-free (Amersham), 
by the following procedure. EGF (10 pug) was 
dissolved in 10 ~1 phosphate buffer (0.1 M, pH 
7.4), 5 pl(500 &i) of Na”‘I, 10 ~1 (1.8 IU) of lac- 
toperoxidase and 10 ~1 of 1 mM Hz02 were added. 
The iodination mixture was incubated for 20 min 
at room temperature and the reaction then stopped 
by the addition of 200 ~1 of ice-cold 0.1 M 
phosphate buffer containing bovine serum 
albumin (2Oro). 
The iodination mixture was applied to a 
Sephadex G-50 column (30 x 1.2 cm) and eluted 
with phosphate buffer 0.1 M (pH 7.4), containing 
NaCl (50 mM) and BSA (0.1 (r/o). The peak of ac- 
tivity corresponding to 2.2 x breakthrough 
volume was applied to an Amberlite IRA 400 ion- 
exchange column (15 x 1.2 cm) and the resulting 
peak pooled and stored at -70°C. By this pro- 
cedure 12’I-EGF of spec. act. 28-40 Ci/g was 
obtained. 
2.2. Preparation of thyroid membranes 
Porcine thyroid tissue was collected fresh from 
a local abattoir and maintained on ice during the 
preparation. Fat and connective tissue was remov- 
ed and discarded, cubes of tissue were homogenis- 
ed in 8-10 vol. Tris (10 mM) buffer on a polytron 
tissue blender. The homogenates were centrifuged 
at 800 x g for 10 min at 4”C, the pellet resuspend- 
ed in 5 vol. Tris buffer and glass-glass homogenis- 
ed. The suspension was centrifuged at 10000 x g 
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for 20 min at 4°C and the pellet resuspended in tion at 10000 x g for 20 min at 4°C. The superna- 
10 mM Tris buffer + NaCl50 mM + BSA 1% (pH tant was aspirated and the radioactivity in the 
7.4) to give the appropriate concentration. pellet counted. 
The protein concentration of the membrane 
preparation was estimated by the Lowry method 
[ 111. Typically, 1 g tissue would produce 5-10 mg 
of protein in the membrane preparation. 
3. RESULTS 
2.3. 3inding assay for EGF 
Thyroid membrane preparations were diluted in 
Tris-NaCl-BSA buffer such that a 100/~1 ali- 
quot/tube gave a final membrane protein concen- 
tration of 1 mg/ml. A 200~1 aliquot/tube of 
serially diluted ‘cold’ EGF and 100 ~1 of 1251-EGF 
dilution (20 pg, 5000 cpm) was added to each tube. 
Tubes were incubated for 1 h at 26°C in a shaking 
water bath, the reaction terminated by addition of 
1 ml of ice-cold Tris-NaCl-BSA buffer and 
bound and free moieties separated by centrifuga- 
3.1. Inhibition of 12sI-EGF binding to porcine 
thyroid membranes by ~nlabe~~ed EGF 
The inhibition of “‘1-EGF binding to porcine 
thyroid membranes by unlabelled EGF has been 
demonstrated (fig.1). The lower limit of detection 
of EGF was -8 pmol/l (50 pg/ml). No further 
decrease in ‘*‘I-EGF binding was detected above 
82 nmol/l unlabelled EGF concentration which 
was consequently used to estimate non-specific 
binding. 
Fig.2 illustrates the effect of thyroid membrane 
protein concentration on the binding of “‘1-EGF; 
a membrane protein concentration of 1 mglml was 
selected and used for all subsequent experiments. 
Fig.1. inhibition of binding of “‘1-EGF to porcine 
thyroid membranes by: (a) unlabelled EGF; (b) bovine 
TSH (mean + SEM, n = 3). 
3.2. Effect of incubation temperature on the time 
course of ‘2SI-EGF binding 
Fig.3 illustrates the effect of incubation 
Fig.2. Effect of membrane protein concentration on the 
binding of 1251-EGF to thyroid membranes. Final 
membrane protein concentration: (a) 1 .O mg/ml; (b) 
0.5 mglml; (c) 0.25 mg/ml; (d) 0.125 mg/ml. Values 
not corrected for non-specific binding (mean +: SEM, 
n = 3). 
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Fig.3. Effect of incubation temperature on the time course of ‘251-EGF binding to porcine thyroid membranes: (-)
total binding; (---) non-specific binding (mean + SEM, n = 3). 
temperatures of 26°C and 37°C on the total and 
non-specific binding of ‘%EGF to porcine 
thyroid membranes. Some degradation of EGF- 
receptor binding was noted after 1 h incubation at 
37’C but not at 26°C. No significant temperature- 
or time-dependent effect on non-specific binding 
was noted. 
3.3. Scatchard analysis of EGF binding to porcine 
thyroid membranes 
Scatchard analysis of EGF binding (fig.4) iden- 
tified receptor sites of high affinity (Ka 1.7 x 
10’ M-l) and low capacity (2.5 x lo-” M/mg 
membrane protein). At higher concentrations of 
ligand the participation of lower affinity binding 
sites is indicated. This experiment was repeated a 
further 4 times and similar values obtained. 
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3.4. Specificity of EGF binding to porcine thyroid 
membranes 
The specificity of EGF binding to porcine 
thyroid membranes was investigated by measuring 
the inhibition of “‘1-EGF binding caused by cross- 
reacting hormones. Fig.1 illustrates the lack of 
cross-reactivity of bovine TSH (Thytropar, Ar- 
mour Pharmaceuticals) at concentrations that in- 
hibit all specific 1251-TSH binding (see fig.5). Table 
1 demonstrates the absence of ‘*‘I-EGF binding in- 
hibition resulting from incubation with various 
other peptide hormones. 
Fig.5 illustrates the lack of cross-reactivity of 
EGF with porcine TSH receptors, as measured by 
the inhibition of binding of ‘*?-TSH (40 pg, spec. 
act. 77.3 Ci/g) to porcine thyroid membranes 
(0.6 mg membrane protein/ml). 
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Fig.4. Scatchard analysis of EGF binding to porcine 
thyroid membranes. 
4. DISCUSSION 
This study clearly demonstrates the presence on 
porcine thyroid cell membranes of receptors for 
epidermal growth factor. These receptors are 
specific, saturable and of high affinity (Ka 1.7 x 
lo9 M-l). High concentrations of bovine TSH did 
not inhibit the binding of 1251-EGF to thyroid 
membranes, nor did EGF inhibit 12’1-TSH bind- 
ing. The binding affinity of porcine thyroid EGF 
receptors is similar to values quoted for EGF 
receptors on other cell types (review [3]). 
Epidermal growth factor has been shown both 
to be a potent mitogen to ovine thyroid cells in 
culture [5] and to control the proliferation and the 
expression of differentiation of canine thyroid cells 
in culture [6]. However, other studies have failed 
to demonstrate an effect by EGF on the prolifera- 
tion of rat [7,9] or bovine [7] thyroid cells. The 
reason for these discrepancies is not clear but 
might involve differences in responsiveness of the 
experimental species used. EGF is a physiologically 
occurring plasma hormone [12] which has also 
been extracted from thyroid tissue [13]. The 
demonstration of EGF receptors on thyroid cell 
membranes indicates that thyroid tissue may be a 
Fig.5. Inhibition of binding of “‘1-TSH to porcine 
thyroid membranes by: (a) unlabelled TSH; (b) EGF 
(mean k SEM, n = 3). 
Table 1 
Effect of various hormones on the binding of lz51-EGF 
to porcine thyroid membranes 
Hormone Cont. “‘I-EGF 
% bound 
(mean + SEM) 
None 
EGF 
hTSH 
LH 
FSH 
ACTH 
Glucagon 
Insulin 
Somatostatin 
- 
82 nmol/l 
54 nmol/l 
17 nmol/l 
17 nmol/l 
6 gmol/l 
70 firnoW 
100 nmol/l 
3 pmol/l 
16.5 + 0.3 
12 k 0.1 
16.5 k 0.4 
15.8 f 0.3 
15.8 IL 0.4 
15.7 + 0.3 
15.7 + 0.1 
15.6 f 0.5 
17.5 + 0.8 
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site of hormonal action of EGF. Further evidence 
for a relationship between EGF and the thyroid 
gland is the T4 stimulation of EGF synthesis by 
neonatal mouse submaxillary glands [ 141. 
This study suggests that EGF may have a 
specific role in the regulation of thyroid follicular 
cell growth and function in normal and 
pathological situations. 
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